Results 271 to 280 of about 324,634 (386)

IMPROVE 2023: The 2nd International Meeting on Pathway‐Related Obesity: Vision & Evidence

open access: yesClinical Obesity, EarlyView.
ABSTRACT A total of 150 clinicians and researchers representing 19 countries came together in person and online to participate in the highly anticipated 2nd International Meeting on Pathway‐Related Obesity: Vision & Evidence (IMPROVE), held on 13–15 December 2023 in Paris, France.
Karine Clément   +19 more
wiley   +1 more source

Is Leptin Concentration Associated with the Insulin Resistance Syndrome in Nondiabetic Men?

open access: bronze, 1999
Steven M. Haffner   +4 more
openalex   +1 more source

Do Obesity Classifications Create the Obesity Paradox? A Scoping Review of Obesity Definitions Applied in Sepsis Research

open access: yesClinical Obesity, EarlyView.
ABSTRACT Obesity appears to be associated with improved health outcomes in patients with sepsis, a phenomenon termed the obesity paradox. However, the potential influence of varying operational definitions of obesity on clinical outcomes within this paradox remains inadequately characterised.
Efris Kartikasari   +2 more
wiley   +1 more source

Influence of Maternal Glycemia on Breast Milk Composition and Volume Ingested by Infants of Mothers With Type 1 Diabetes. [PDF]

open access: yesDiabetes Care
Donovan LE   +8 more
europepmc   +1 more source

Regulation of Neuronal and Glial Proteins by Leptin: Implications for Brain Development* [PDF]

open access: bronze, 1999
Rexford S. Ahima   +3 more
openalex   +1 more source

Short Term Effects of Leptin on Hepatic Gluconeogenesis and in Vivo Insulin Action [PDF]

open access: hybrid, 1997
Luciano Rossetti   +7 more
openalex   +1 more source

Neurobeachin (NBEA) is a novel gene associated with GLP‐1 receptor agonist associated weight loss

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Nearly 42% of adults in the United States have obesity, a significant risk factor for many cardiometabolic diseases and cancers. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are promising interventions for weight loss, but their efficacy varies significantly across individuals.
Arshiya Mariam‐Smith   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy